Akshaya Bio, Inc.

Akshaya Bio is a privately held Canadian biotechnology company, developing innovative therapeutics for infectious diseases and cancer, using its proprietary and novel Chimigenë Platform.

Akshayas proprietary Chimigenë Platform was acquired from Paladin Labs and ViRexx Medical Corp., and is used for the development of Chimigenë Vaccines.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://www.akshayabio.com
Disease Focus
STOCK CODENon Listed
Address
8223 Roper, Alberta T6E 6S4
Edmonton
Canada
Email
Contact Number
+1 780-433-4411

Akshaya Bio is a privately held Canadian biotechnology company, developing innovative therapeutics for infectious diseases and cancer, using its proprietary and novel Chimigenë Platform.

Akshayas proprietary Chimigenë Platform was acquired from Paladin Labs and ViRexx Medical Corp., and is used for the development of Chimigenë Vaccines.

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]

Chimigenë Vaccine Platform is designed to elicit both humoral and cellular immune responses in hosts. Chimigenë Vaccines are recombinant proteins that have selected antigens fused to the Fc fragment of a murine monoclonal antibody through proprietary peptide linkers.

Pipeline

Various Chimigenë Cancer Vaccine targets are under evaluation/development, and includes MUC1, Carbonic anhydrase IX (CA9), Carcinoembryonic antigen (CEA).